AbbVie’s recent performance and what it might mean for investors AbbVie (ABBV) has seen its share price record a 1 day return ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie’s latest valuation update comes with only a marginal trim to its fair value estimate, shifting from about US$244.68 to ...

AbbVie (ABBV) has been drawing fresh attention after recent share price moves, with the stock showing mixed returns over the ...

AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more ...

AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is ...

While management did not quantify any potential tariff exposure, it did signal that the effect would be in line with the industry impact. AbbVie ABBV reported 8.4% revenue growth and 6.5% adjusted ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. In addition, this pharmaceutical company’s growth prospects are high, now that its purchase of Allergan is closed. For ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...